# PR1054 work report — Writer2 W2.17 RESTRAINT product/runtime qualification

## CURRENT STATE — READ FIRST

```text
HANDOVER_READINESS: READY
REPOSITORY: reallaksh19/XML_Compare_Utilities
SOURCE_ISSUE: #1052
PR: #1054
BRANCH: agent/cii-writer2-restraint-product-runtime-w217
BASE_MAIN: 3a681c1c587ee3c1462a962879e4f79433258105
PREDECESSOR: PR #1053 / W2.16 / squash merged
WORK_INTENT: INVESTIGATE / VALIDATE
CRITICALITY: ENGINEERING_CRITICAL
MUTATION_AUTHORITY: READ_ONLY_QUALIFICATION
PRODUCTION_CHANGE_AUTHORITY: FALSE_BY_DEFAULT
MERGE_AUTHORITY: OWNER_ONLY
MERGE_AUTHORIZED: FALSE
PR_STATE: DRAFT
CURRENT_GATE: W2_13_PRODUCT_RUNTIME
RELEASE_FREEZE: NOT_READY_FOR_WRITER2_RESTRAINT_DELETE_RELEASE_FREEZE
```

## Inherited observed truth

```text
W2.11 RESTRAINT P01-P06/P19/P07-P18 = PASS_RUNTIME_EXACT_BLOB
W2.12 R01-R22                        = PASS_RUNTIME_EXACT_BLOB
W2.13 synthetic product              = NOT_RUN_ENVIRONMENT
W2.13 retained-real-CII product      = NOT_RUN_ENVIRONMENT
remaining Writer2 regressions        = PARTIAL_PASS_W2_11_RESTRAINT_ONLY
repository npm                       = NOT_RUN_ENVIRONMENT
engineering failure                  = NONE_OBSERVED
```

## Binding authority / negative assurance

- CONTROL row1 / field4 / I13 = NONAM: preserve byte-identically.
- CONTROL row2 / field4 / I13 = RESTRAINTS: qualified RESTRAINT block-count mutation.
- RESTRAINT CREATE remains blocked.
- SIF CREATE remains blocked.
- HANGER CREATE remains blocked.
- Writer3 topology remains blocked/unchanged.
- Parser/converter semantics remain unchanged.
- No workflow changes without separate authorization.
- No production mutation unless an authored assertion first fails and the defect is isolated.

## Coordination

Live open Writer2 PR #1033 is SIF CREATE qualification only. W2.17 may consume merged SIF DELETE authority read-only but must not consume or widen SIF CREATE authority. No competing RESTRAINT runtime PR was found at initialization.

## Mandatory execution order

1. `node tests/cii-workspace-writer2-restraint-product-routing.test.js`
2. `node tests/cii-workspace-writer2-restraint-product-real-cii.test.js`
3. inherited Writer2 regression slice:
   - `node tests/cii-workspace-writer2-composite-product-routing.test.js`
   - `node tests/cii-workspace-writer2-hanger-partial-product.test.js`
   - `node tests/cii-workspace-writer2-hanger-partial-deleted-testimony.test.js`
   - `node tests/cii-workspace-writer2-real-benchmark-roundtrip.test.js`
   - `node tests/cii-workspace-writer2-trifamily-real-benchmark-roundtrip.test.js`
4. `npm ci && npm test` only if complete exact checkout becomes available; otherwise keep NOT_RUN_ENVIRONMENT.
5. Issue evidence-based READY/NOT_READY freeze verdict.

## Changed-file ledger

Current intended repository diff is evidence-only:

```text
agents/PR1054_workreport.md
agents/status/PR1054.yaml
agents/claims/PR1054.yaml
```

Temporary `agents/WIP-w217-restraint-product-runtime_workreport.md` is initialization-only and must be removed after permanent records exist.

## Appendix A — takeover qualification

A1 Production trace: trace Writer2 RESTRAINT DELETE through W2.11 physical compaction, W2.12 one-TARGET0 arbitration, W2.13 core dispatch/product validation, canonical re-intake, and final bytes.

A2 Failure isolation: distinguish missing exact dependency/module-load stop from authored assertion failure; only the latter can justify production correction.

A3 Authority invariant: protect CONTROL row1/NONAM vs row2/RESTRAINTS I13 custody and preserve CREATE/topology blockers.

A4 Independent validation: W2.13 must terminate in the independent complete-postimage validator, not Writer testimony alone.

A5 Minimal patch: if an authored assertion fails, first capture raw failure and identify the smallest authority-preserving correction; do not widen CREATE/parser/topology scope.

## EXACT_NEXT_ACTION

Remove the WIP record, re-use `/mnt/data/w215` where exact production/test blobs are unchanged by the evidence-only PR1053 merge, verify required entrypoint/dependency blobs against current `main`, and execute W2.13 synthetic product routing then retained-real-CII qualification.
